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ABSTRACT
Background: The prevalence of bronchial asthma (BA) in youth is increasing in Japan, but very few athletes
are reported to be affected with BA. The aim of this study is to analyze pulmonary function test (PFT) in athletes
from the aspect of BA retrospectively.
Methods: Medical history questionnaires of 2111 athletes (male: 1549, female: 562) were reviewed. All ath-
letes participated in the institute’s athletic test for the first time, from April 2003 through March 2006. Athletes
were categorized into three groups; current-BA confirmed and treated by the physician, possible-BA according
to the allergic history andor BA symptoms, and non-BA that is neither of the above two groups. The PFT data
were then analyzed.
Results: There were 24 current-BA (1.1%), 137 possible-BA (6.5%), and 183 cases with a past history of BA
(PH; 8.7%). Percent of predicted forced expiratory volume in 1 second (%FEV1) and of predicted peak expira-
tory flow rate (%PEF) in current-BA (86.2 ± 17.7% and 81.6 ± 19.1%, respectively) and possible-BA (84.7 ±
14.6% and 81.2 ± 17.3%, respectively) were significantly lower than those in non-BA (93.9 ± 13.7% and 93.8 ±
19.8%, respectively), without any significant difference between current-BA and possible-BA. Athletes with PH
show impaired obstructive indices; even in non-BA with PH showed lower %FEV1 (91.3 ± 13.9%, p < 0.05) and
%PEF (86.8 ± 17.8%, p < 0.001) than non-BA without PH (94.0 ± 13.7% and 94.2 ± 19.9%, respectively).
Conclusions: The incidence of BA in Japanese athletes may be higher than currently recognized. More inter-
vention is encouraged for the diagnosis of BA, to avoid any fatal asthma during sports by initiating preventive
therapy.
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INTRODUCTION
A negligible number of Japanese athletes requested
the use of an inhaled beta agonist (IBA) at recent
Olympic Games1; only one out of 268 athletes from
Japan applied for permission at the Sydney Games,
where 112 out of 594 athletes from the United States
of America notified the use. This low prevalence of
notification by Japanese athletes may be partly due to
the relatively low prevalence of bronchial asthma
(BA) patients in Japan.
The prevalence of BA among Japanese children
has increased by 3% in the last 20 years, and two re-
cently conducted government surveillances have re-
vealed the rate in school-age children to be 5.7 and
7.6%. In 2003, the Global Initiative for Asthma (GINA)
also reported a similar rate of 6.7% as the prevalence
of BA symptoms in Japanese school-age children,
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Table 1 Medical questionnaire regarding history and symptoms of bronchial asthma and alergy
BA† history:
1. Is the athlete on the folow-up of BA at the clinic? (curent-BA)
2. Has the athlete been diagnosed as BA during the childhood? (PH‡ )
BA symptoms:
3. Has the athlete ever been diagnosed as alergic disease other than BA?
4. Has any of the family (siblings or parents) been diagnosed as BA?
5. Does the athlete experience wheezing, chest tightness, breathlessness, cough, or excess of sputum at night or early in the 
morning?
6. Does the athlete experience wheezing, chest tightness, breathlessness, cough, or excess of sputum after exposure to the cer-
tain airborne substances (alergens or polutants)?
7. Does the athlete experience wheezing, chest tightness, breathlessness, cough, or excess of sputum during and after the ex-
ercise?
8. Does the athlete experience wheezing, chest tightness, breathlessness, cough, or excess of sputum as the seasonal exacer-
bation?
9. Do the athlete’ s colds take more than 14 days to clear up?
(One point for each “yes” answer to question 3 through 9, and the athlete is considered possible-BA if the score is three or 
greater.)
†BA, bronchial asthma.
‡PH, past history of asthma.
which is below the rate for the United States of Amer-
ica, 10.9%.2
The prevalence of BA in athletes is higher than in
the general population,3-7 and considering the differ-
ence in prevalence between Japan and the United
States of America shown above, many Japanese ath-
letes possibly have undiagnosed BA; the percentage
of Japanese athletes who applied for the use of IBA is
too low referring to the prevalence of BA among Japa-
nese children. Moreover, there is no published report
so far, regarding the prevalence of asthma-related dis-
orders among Japanese athletes.
Thus, we have decided to analyze the baseline pul-
monary function test (PFT) data regarding the BA
background of athletes, since our medical question-
naire for the health check-ups included the BA-
related history and symptoms. Recent studies show
that the medical questionnaires or interviews are not
reliable in identifying the exercise-induced bron-
chospasm (EIB).8 EIB should be documented by
evaluating the PFT in response to appropriate exer-
cise or provocation tests. However, medical history is
still a helpful guide in the clinical diagnosis of BA,
and can be used in screening of BA regardless of
EIB.
The primary aim of this study was to analyze
screening PFT of Japanese athletes from the aspect
of BA, by the groups categorized through the scoring
of a medical questionnaire regarding asthma symp-
toms and allergic history.
METHODS
STUDY DESIGN
We conducted a cross-sectional retrospective study of
regional elite athletes who participated in their first
athletic test performed at the Niigata Institute for
Health and Sports Medicine, from April 2003 through
March 2006. A total of 2111 athletes (1549 males, 562
females, age 18.0 ± 4.1 years) were included in this
study. The data from screening tests were collected
during the preparticipation health check-ups, includ-
ing a medical questionnaire focused on history and
symptoms of BA and allergy (Table 1), and baseline
PFT. The study procedures including participant’s
anonymity preservation were approved by the Ethical
Committee of the Niigata Institute for Health and
Sports Medicine in accordance with the principles
embodied in the Declaration of Helsinki, and each
subject, parents, or legal guardian provided written
informed consent.
ASTHMA AND ALLERGY QUESTIONNAIRE
A detailed BA and allergy history and review of symp-
toms were obtained using a medical questionnaire as
shown in Table 1. The questionnaire consisted of 9
items relevant to the diagnosis of BA, also referring
to the medical history consideration shown by
GINA,9 and an athlete was categorized as current-BA,
possible-BA, or non-BA. The athlete was considered
current-BA if BA was confirmed and treated by the
physician, possible-BA if scoring 3 or more items for
the allergic history andor BA symptoms, and non-
BA if the athlete was neither current-BA nor possible-
BA. Possible-BA, however, was defined as above in
this study to categorize athletes into groups, simply
for the sake of convenience to analyze baseline PFT
retrospectively.
PULMONARY FUNCTION TEST BY SPIROME-
TRY
A baseline PFT by spirometry was performed for all
participants. The best value from three measure-
ments of vital capacity (VC), forced vital capacity
(FVC), forced expiratory volume in one second
Pulmonary Function Analysis in Athletes
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Table 2 Categorical characteristics of the participants
Male/FemaleNumber (%)
1549/5622111 (100) Total participants
  17/7  24 (1.1)Curent-BA
  15/5)  20(PH+
  97/40 137 (6.5)Possible-BA
  40/8)  48(PH+
1435/5151950 (92.4)Non-BA
  80/35) 115(PH+
(FEV1), peak expiratory flow (PEF) were used and
recorded by a spirometer, SpiroSift SP-470 (Fukuda
Denshi, Tokyo, Japan.). Predicted values were calcu-
lated by the standard formulae originally pro-
grammed in the spirometer.
DATA ANALYSIS AND STATISTICS
Percent of predicted FEV1 (%FEV1), percent of pre-
dicted PEF (%PEF), and FEV1FVC (FEV1%) were
analyzed for each category of athletes, current-BA,
possible-BA, and non-BA. The data were further ana-
lyzed according to the past history of asthma (PH)
status. Values for all measurements are expressed as
mean (%) ± SD.
Kruskal-Wallis test, and Mann-Whitney U tests
were used to determine the levels of difference be-
tween all groups. Significance was assumed at p-
values of <0.05.
RESULTS
There were 24 current-BA (1.1%), 137 possible-BA
(6.5%), and 1950 non-BA (92.4%) cases. In 183 cases
of PH (8.7%), there were 20 current-BA, 47 possible-
BA, and 116 non-BA cases. Considering the rate of
PH, cumulative morbidity of BA was estimated as
8.9%. The difference between male and female ath-
letes was not discussed in this study, because 562 fe-
male athletes were analyzed, and there were only
seven cases with current-BA and 40 cases with
possible-BA, which resulted in numbers that were too
few to see any significance (Table 2).
As shown in Figure 1, current-BA showed a signifi-
cantly decreased %FEV1 (current-BA vs. non-BA;
86.2 ± 17.7% vs. 93.9 ± 13.7%), %PEF (81.6 ± 19.1% vs.
94.3 ± 26.2%) and FEV1% (84.6 ± 8.3% vs. 89.0 ± 5.8%)
compared to non-BA, even under the relevant treat-
ment (p < 0.001). Interestingly, possible-BA is also
significantly decreased in pulmonary function pa-
rameters compared to non-BA (possible-BA vs. non-
BA; 84.7 ± 14.6% vs. 93.9 ± 13.7% in %FEV1, 81.2 ±
17.3% vs. 94.3 ± 26.2% in %PEF, and 84.9 ± 7.5% vs.
89.0 ± 5.8% in FEV1%, all with p < 0.001, respectively).
However, there was no significant difference between
current-BA and possible-BA (Fig. 1). %VC, which is
one of restrictive indices in PFT, was of no difference
among all groups (data not shown).
To determine the influence of PH on pulmonary
function, comparison between groups either with or
without PH was performed. Among all participants,
the group with PH (PH+) showed decreased pulmo-
nary function parameters compared to the group
without PH (PH−) (PH+ vs. PH−; 89.9 ± 14.3% vs.
93.5 ± 14.0% in %FEV1, p < 0.001. 87.2 ± 17.8% vs.
93.4 ± 20.0% in %PEF, p < 0.005. 86.8 ± 6.6% vs. 88.8 ±
6.0% in FEV1%, p < 0.001.). In regard to non-BA, PH+
also revealed decreased airway function compared to
PH− (PH+ vs. PH−; 91.3 ± 13.9% vs. 94.0 ± 13.7% in
%FEV1, p < 0.05. 86.8 ± 17.8% vs. 94.2 ± 19.9% in %PEF,
p < 0.001. 87.3 ± 6.0% vs. 89.1 ± 5.8% in FEV1%, p <
0.005.). In contrast, when the samples are limited to
possible-BA, the findings were vice versa; PH− had
decreased airway function in comparison with PH+
(PH+ vs. PH−; 87.6 ± 13.1% vs. 83.2 ± 15.2% in %FEV1,
p = 0.104. 89.0 ± 17.6% vs. 77.1 ± 15.7% in %PEF, p <
0.005. 86.8 ± 6.8% vs. 84.0 ± 7.7% in FEV1%, p < 0.05.).
And even in 24 current-BA, though sample numbers
were too small to make conclusions, PH− in this cate-
gory had a tendency for decreased airway function
compared to PH+ except for FEV1% (PH+ vs. PH−;
87.0 ± 18.5% vs. 81.6 ± 14.4% in %FEV1. 84.2 ± 19.5% vs.
67.3 ± 10.8% in %PEF. 84.5 ± 8.5% vs. 85.1 ± 7.8% in
FEV1%.) (Table 3).
DISCUSSION
The study by Hammerman, et al. showed that there
were 5.7% BA or EIB among American high school
athletes, and another 6.1% were identified as having
undiagnosed BA.10 In the present study, although the
athletes defined as possible-BA were not medically
confirmed as BA at the time of visit, the obstructive
indices of PFT showed similar results compared with
current-BA. These data suggest that a considerable
number of these athletes may also have undiagnosed
BA.
A recent nation-wide survey on the health and wel-
fare status by the Japanese government revealed that
71.3% of the all-age patients with BA symptoms were
under antiasthmatic medication, but only 54.6% of
such patients aged between 15 and 34 years were un-
der relevant treatment.11 Of 161 athletes with either
current-BA or possible-PA in our study, less than 15%
of them were current-BA who were on medication,
thus indicating that the prevalence of untreated BA
may also be higher among athletes. Importantly, a 7-
year observation of BA deaths by Becker, et al. report
that of 61 casualties during sport activities, 55 cases
had mild intermittent or persistent BA before their fa-
tal attack, and that only 3 of them used long-term con-
troller medication.12 Although most of the non-
current-BA athletes tested in our study had little res-
piratory symptoms during and after the usual exer-
cise, the undiagnosed BA should thoroughly be de-
tected, in order to avoid any future BA deaths related
to exercise and sport activities.
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Table 3 Obstructive indices of pulmonary function test in athletes with or without past history of asthma.
FEV1% (%)%PEF (%)%FEV1 (%)
Al participants
86.8 ± 6.6***87.2 ± 17.8**89.9 ± 14.3***(n = 183)PH+
88.8 ± 6.093.4 ± 20.093.5 ± 14.0(n = 1928)PH-
Curent-BA
84.5 ± 8.5†84.2 ± 19.5†87.0 ± 18.5†(n = 20)PH+
85.1 ± 7.867.3 ± 10.881.6 ± 14.4(n = 4)PH-
Possible-BA
86.8 ± 6.8*89.0 ± 17.6**87.6 ± 13.1(n = 48)PH+
84.0 ± 7.777.1 ± 15.783.2 ± 15.2(n = 89)PH-
Non-BA
87.3 ± 6.0**86.8 ± 17.8***91.3 ± 13.9*(n = 115)PH+
89.1 ± 5.894.2 ± 19.994.0 ± 13.7(n = 1835)PH-
Data express mean ± SD, *p < 0.05, **p < 0.005, ***p < 0.001; compared with PH-.
† Insuficient sample numbers for statistical analysis.
Fig. 1 Obstructive indices of pulmonary function tests (%FEV1, %PEF, and 
FEV1%) in athletes. Data express mean (%) ± SD. * p < 0.001 by the Kruskal-Wal-
lis test.
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Another important message is derived from the re-
sults concerning the influence of PH on pulmonary
function. The present study has shown that athletes
with PH, who were even considered as non-BA, had
impaired pulmonary function indices, suggesting
they may not have fully recovered from their child-
hood asthma. In general, it has been reported that up
to 70% of BA patients in childhood lose their symp-
toms during puberty.13,14 Osward, et al. conducted 28-
year follow-up study for mild asthmatics in childhood,
and suggested that airway obstruction or hyperre-
sponsiveness of the patients would be restored nor-
mally even if they did not use inhaled corticoster-
oids.15 On the contrary, Agertoft, et al. showed that a
delay in the introduction of inhaled corticosteroids re-
sulted in incomplete recovery of pulmonary func-
tion.16 Moreover, Pederson, et al. reported that early
intervention with sufficient doses of inhaled corti-
costeroids could cure the disease with no recur-
rence.17 In this regard, our data may also indicate the
possible insufficiency of the treatment approach to
childhood BA leading to the symptom takeover
through the youth generation, and we should be care-
ful with PH+ in non-BA patients who have little BA
symptoms. Another valuable finding regarding the ef-
fect of PH status is that PH− in possible-BA had de-
creased airway function compared with PH+. This ten-
dency is also observed in current-BA (Table 3). Al-
though the details in the treatment history of BA is
limited in the medical record, it is more likely that
PH+ in these categories received treatment interven-
tion in the past, which may apparently improve the
respiratory function, assuming possible-BA has high
potential for being true BA.18
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We included questionnaires of respiratory symp-
toms and PFT at baseline medical check-ups, with the
belief that these findings are important in the clinical
diagnosis of BA. However, they may be insufficient
for the diagnosis of EIB. Rundell, et al. found that
among elite athletes, a diagnosis based on self-
reported symptoms is no more accurate than a coin
toss. In that study, 61% of EIB-positive athletes re-
ported symptoms, and 45% of normal pulmonary func-
tion athletes reported symptoms of EIB.19 Meth-
acholine challenge test is often used for BAEIB di-
agnosis in Japan, but it should be noted that a rela-
tively low sensitivity for EIB diagnosis especially in
summer sports is reported for this provocation.20 We
have recently started additional bronchial challenge
tests such as eucapnic voluntary hyperpnea and hy-
pertonic saline inhalation, together with exercise
challenge which are the current challenge tests also
recommended by the International Olympic Commit-
tee for the diagnosis of BAEIB in athletes.
In summary, the PFT results at the Niigata Insti-
tute for Health and Sports Medicine were analyzed,
according to the historical background of BA, and the
prevalence of current-BA, possible-BA, and the cumu-
lative morbidity of BA among the regional elite ath-
letes were 1.1, 6.5, and 8.9%, respectively. A limitation
of this study is in the retrospective analysis using a
medical questionnaire, of which data had been
adopted from sufficient but non-uniform medical re-
cord formats. The effectiveness of this medical ques-
tionnaire in the uniform medical record format on
scoring should be confirmed, and is currently under
prospective investigation.
Finally, considering the epidemiological data on
BA in athletes available so far, the incidence of BA
among the Japanese athletes may be higher than cur-
rently recognized. More intervention is encouraged
for diagnosing BA and related subtypes to avoid any
fatal asthma attacks during sport activities, and to re-
store originally expected athletic performance of the
affected individuals.
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